Monte Rosa Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDMonte Rosa Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 92), indicating clear outperformance against the broad market. Earnings contraction of 219% provides fundamental context to the price action. However, price is extended 25% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $20.31 | +20.13% | ABOVE |
| 50 SMA | $19.46 | +25.41% | ABOVE |
| 100 SMA | $18.54 | +31.62% | ABOVE |
| 150 SMA | $18.78 | +29.96% | ABOVE |
| 200 SMA | $16.79 | +45.33% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is GLUE in an uptrend right now?
GLUE has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is GLUE overbought or oversold?
GLUE's RSI (14) is 68. The stock is in neutral territory, neither overbought nor oversold.
Is GLUE outperforming the market?
GLUE has a Relative Strength (RS) Rating of 92 out of 99. Yes, GLUE is a market leader, outperforming 92% of all stocks over the past 12 months.
Where is GLUE in its 52-week range?
GLUE is trading at $24.40, which is 95% of its 52-week high ($25.77) and 94% above its 52-week low ($4.12).
How volatile is GLUE?
GLUE has a Beta of 1.16 and 52-week volatility of 92%. It's more volatile than the S&P 500 - expect bigger swings.